/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
March 20, 2023 at 7:13 PM
An updated Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 98-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia
June 3, 2020 at 12:34 PM
An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia
November 22, 2011 at 10:28 AM
This morning, CEL-SCI Corp. (CVM-NYSE Amex) announced the completion of its clinical investigator meeting held last week in Prague. The meeting, which included clinical investigators and research associates, medical monitors, quality assurance personnel, and CEL-SCI’s scientific and management teams, was held to provide protocol and Good Clinical Practice (GCP) training in anticipation of the start of CEL-SCI’s upcoming Phase III trial of Multikine® in advanced primary head and neck cancer. More than 120 participants from nine countries were present to ask questions about clinical trial conduct.
Topics: Newsworthy Events, CEL-SCI
February 14, 2011 at 9:50 AM
Last week, several companies within our coverage universe released financial results and corporate updates, including CEL-SCI Corporation (CVM-NYSE Amex), Pro-Pharmaceuticals Inc. (PRWP-OTC), and Advaxis Inc. (ADXS-OTC). In addition, Neuralstem, Inc. (CUR?-NYSE Amex)? announced a breakthrough in its clinical trials that it believes could greatly influence the treatment of amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease—a potentially fatal neuromuscular disorder.
Topics: Newsworthy Events, Advaxis, CEL-SCI, Multikine
January 5, 2011 at 10:11 AM
As we kick off the New Year, many companies within our Coverage Universe are showing a positive start to 2011. For example, Canadian biopharmaceutical company Bioniche Life Sciences Inc. (BNC-TSX) recently raised A$12.5 million in Australia. Biotechnology company Xoma Ltd. (XOMA-NASDAQ) signed a development and licensing agreement potentially valued up to $505 million for an anti-inflammatory drug candidate. In addition, Advanced Cell Technology, Inc. ([“ACT”] ACTC-OTC.BB), a regenerative medicine company, announced that the FDA has cleared its Investigational New Drug application (IND) to test a therapy made from embryonic stem cells in patients with macular degeneration, a leading cause of vision loss. Further, the Tel-Aviv Stock Exchange (TASE) approved the inclusion of Pluristem Therapeutics Inc.’s (PSTI-NASDAQ) ordinary shares on four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA, and Biomed.
Topics: Newsworthy Events, Bioniche, Pluristem Therapeutics, CEL-SCI
December 8, 2010 at 10:22 AM
News from our coverage universe this week includes Johnson & Johnson’s bid to buy Crucell for $2.3 billion, the distribution of two of Bioniche’s cattle reproduction products in Australia, the latest advances in CEL-SCI’s Multikine® manufacturing and laboratory operations, and the upcoming release of Peregrine’s 2Q2011 financial results.
Topics: Crystal Research Associates, Newsworthy Events, Bioniche, CEL-SCI
October 13, 2010 at 10:48 AM
CEL-SCI Corporation (CVM-NYSE Amex) is advancing its Phase III clinical trial of Multikine®, CEL-SCI’s lead immunotherapy product. Multikine® is being developed as a first-line standard-of-care treatment for head and neck cancer. In previous Phase II trials, this therapy was safe and well-tolerated, and had increased patient survival by 33% at a median of 3.5 years after treatment. Multikine® was also credited with eliminating head and neck cancer tumors in 12% of patients less than a month into treatment. On average, CEL-SCI’s new cancer therapy kills about 50% of tumor cells before patients have surgery or begin chemotherapy, which improves the likelihood of success of these standard treatments.
Topics: Newsworthy Events, CEL-SCI, Multikine
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS